February 14, 2023, San Diego, California — Ryne Biotechnology, Inc. (Ryne Bio), a therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological disorders, announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4 million Clinical Stage Research Program (CLIN1) grant. This funding will enable the company to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application within the next 12 months. [Read more…]
EV Biologics Generates Mesenchymal Stem Cell Lines
TAMPA, FL, February 21, 2023 – EV Biologics Corp (OTC PINK:YECO), announced that it has successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. The cell banks were isolated from rigorously screened human donor tissue using xeno-free, serum-free culture media for isolation and expansion, after obtaining informed consent (from donors) for research and development. Analysis of the cell lines confirmed their identity as MSCs according to established criteria. [Read more…]
Heartseed and Novo Nordisk Dose First Patient with HS-001, an iPSC-Derived Cell Therapy to Treat Heart Failure
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).
Clinical phase 1/2 study (LAPiS Study) will enroll 10 patients with advanced heart failure caused by ischaemic heart disease.
Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. [Read more…]
WORLD ORGANOID RESEARCH DAY (a Free Global Event) Attracts Leading Researchers & Technologies, March 22, 2023
February 28, 2022, Hertfordshire, United Kingdom – World Organoid Research Day, an OrganoidSpheroid.com initiative, has announced a world-leading speaker lineup of key organoid and organ-on-a-chip researchers and technologies. It is free to attend both globally online via ZOOM/LinkedIn and in person in UK, supported by sponsors Qkine Limited and CN-BIO.
You can register to secure your space here: www.organoidspheroid.com. Only registered attendees will be able to watch each of the forty 15-minute talks live and on-demand. [Read more…]
The European Innovation Council (EIC) awards the AcouSort project AcouSome SEK 26 million to develop groundbreaking technology for exosome-based diagnostics
August 13, 2022, Lund, Sweden – Exosomes are nanoparticles that enable human cells to communicate vital information with each other. They have potential to open a completely new field within diagnostics, as they can give us ‘status reports’ on organs such as the brain and heart, as well as give us vital information on tumor diseases, infectious diseases, pregnancy and stem cell conditions. EIC has announced that it granted AcouSort and its project partners SEK 26 million to develop an acoustofluidic thin-film actuated chip for exosome separation from blood. Of the SEK 26 million, SEK 12.2 million go directly to AcouSort, and the remainder of the funding is distributed to AcouSort’s partners Lund University, DTU, and Day One. The project will run for 36 months and is fully funded by the EU. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 80
- Next Page »